Type 2 diabetes: safety and efficacy of pioglitazone monotherapy

  • Alam F & al.
  • Sci Rep
  • 29 Mar 2019

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • This meta-analysis supports pioglitazone as an effective treatment option for the management of type 2 diabetes mellitus (T2DM) because of its potential to lower hyperglycaemia, adverse lipid metabolism and blood pressure (BP).

Why this matters

  • Pioglitazone, the only thiazolidinedione drug in clinical practice, is under scrutiny because of reported adverse effects, but its unique insulin sensitising action provides rationale to remain as a therapeutic option for T2DM management.

Study design

  • 16 studies involving 2681 patients with T2DM met eligibility criteria after a search across electronic databases.
  • Efficacy outcomes: mean changes in glycated haemoglobin (HbA1c) level, fasting blood sugar (FBS) level, body weight (BW) and homeostasis model assessment-insulin resistance (HOMA-IR).
  • Safety outcomes: changes in BP, lipid parameters and incidences of adverse events.
  • Funding: None.

Key results

  • Both pioglitazone and comparative monotherapies were equally effective in reducing:
    • HbA1c level (mean difference [MD], 0.05%; P=.56; I2, 81%);
    • HOMA-IR (weighted mean difference [WMD], 0.05; P=.86);
    • BP (WMD, −1.05 mmHg; P=.52); and
    • triglycerides level (WMD, −0.71 mmol/L; P=.16).
  • Pioglitazone monotherapy significantly reduced FBS level (MD, 0.24 mmol/L; P=.04; I2, 65%) and increased BW (WMD, 2.06 kg; P<.0001 vs comparative monotherapies.>
  • Pioglitazone monotherapy was equally effective as comparative monotherapies in increasing high-density lipoprotein level (WMD, 0.02 mmol/L; 95% CI, −0.06 to 0.10).
  • Pioglitazone monotherapy was significantly associated with increased risk for oedema (risk ratio [RR], 2.21; P=.0001) and decreased risk for hypoglycaemia incidence (RR, 0.51; P=.003).

Limitations

  • Heterogeneity among studies.
  • Small sample size.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit